Lilly’s acquisition of Disarm Therapeutics: A milestone in neurodegenerative disease treatment
In a significant move to bolster its portfolio in the field of neurological disease treatments, Eli Lilly and Company (Lilly) has entered into an agreement ... Read More
Bristol Myers Squibb to acquire MyoKardia for $13.1bn: A strategic move to strengthen cardiovascular portfolio
Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has announced an agreement to acquire MyoKardia, a California-based clinical-stage biotechnology company, for $13.1 billion. This ... Read More
Covis Group to acquire US biopharma company AMAG Pharmaceuticals
Covis Group, a Luxembourg specialty pharma company, has agreed to acquire US biopharma company AMAG Pharmaceuticals for about $647 million, which includes the latter’s debt. ... Read More
Permira to acquire Spanish pharma company Neuraxpharm from Apax Partners
Permira, a UK-based private equity firm, said that a company backed by its funds has agreed to acquire Neuraxpharm, a specialty pharma company focused on ... Read More
Roche acquires Irish inflammasome company Inflazome for €380m
Roche acquisition of Inflazome : Swiss drug giant Roche has acquired Irish biotech company Inflazome, a developer of inflammasome inhibitors, for an upfront payment of ... Read More
AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics
Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The ... Read More
Japan-based Santen acquires US ophthalmic company Eyevance Pharmaceuticals
Santen acquisition of Eyevance : Santen Pharmaceutical, a Japanese pharma company specialized in ophthalmology, has acquired US ophthalmic company Eyevance Pharmaceuticals for $225 million in ... Read More
Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy
Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to ... Read More
Nestlé to fully own Aimmune Therapeutics through $2bn deal
Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in ... Read More
Ionis Pharmaceuticals to take full ownership of Akcea Therapeutics
Ionis Pharmaceuticals is set to take full ownership of Akcea Therapeutics by acquiring the remaining stake of around 24% in the latter for about $500 ... Read More